Page last updated: 2024-09-04

tipifarnib and Emesis

tipifarnib has been researched along with Emesis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belly, RT; Bol, CJ; Bowden, C; Chiao, J; Chow, C; Cowan, KH; End, DW; Gress, RE; Hakim, FT; Horak, ID; Kohler, DR; Kopp, WC; Kremer, AB; Larkin, G; Noone, M; Nussenblatt, RB; Piotrovsky, VK; Todd, A; Woestenborghs, R; Zujewski, J1
Bol, CJ; Punt, CJ; Seifert, WF; van Maanen, L; Wagener, DJ1
Beijnen, JH; Boerrigter, L; Bol, CJ; Crul, M; de Gast, GC; de Jong, D; de Klerk, GJ; Palmer, PA; Schellens, JH; Swart, M; Tan, H; van't Veer, LJ1

Trials

3 trial(s) available for tipifarnib and Emesis

ArticleYear
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4

    Topics: Administration, Oral; Adult; Aged; Alkyl and Aryl Transferases; Anemia; Biological Availability; Bone Marrow; Capsules; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Half-Life; Headache; Humans; Hypotension; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Peripheral Nervous System Diseases; Quinolones; Solutions; Vomiting

2000
Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
    Anti-cancer drugs, 2001, Volume: 12, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Biological Availability; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Quinolones; Time Factors; Vomiting

2001
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-01, Volume: 20, Issue:11

    Topics: Administration, Oral; Alkyl and Aryl Transferases; Antineoplastic Agents; Biotransformation; Drug Administration Schedule; Enzyme Inhibitors; Farnesyltranstransferase; Fatigue; Female; Genes, ras; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Nausea; Neoplasms; Quinolones; Vomiting

2002